Lyka Labs Limited (BOM:500259)

India flag India · Delayed Price · Currency is INR
114.10
-0.80 (-0.70%)
At close: Jun 27, 2025
-0.95%
Market Cap 3.95B
Revenue (ttm) 1.35B
Net Income (ttm) 79.03M
Shares Out n/a
EPS (ttm) 2.22
PE Ratio 49.94
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 960
Average Volume 1,771
Open 114.90
Previous Close 114.90
Day's Range 113.75 - 114.90
52-Week Range 90.20 - 175.95
Beta n/a
RSI 40.96
Earnings Date Aug 1, 2025

About Lyka Labs

Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, nutraceuticals, anti-mal... [Read more]

Industry Pharmaceutical Preparations
Founded 1976
Employees 423
Stock Exchange Bombay Stock Exchange
Ticker Symbol 500259
Full Company Profile

Financial Performance

Financial Statements

News

Lyka Labs secures patent for Pregabalin Gel 8% to treat diabetic neuropathic pain

Lyka Labs Limited has announced the grant of an Indian patent for its innovative topical product, Pregabalin Gel 8%, with protection extending until 2043. This milestone underscores Lyka Labs’ commitm...

3 months ago - Business Upturn